Smith & Nephew not behind 20% Corin price rise
This article was originally published in Clinica
Smith & Nephew has denied interest in buying Corin, the UK-listed reconstructive orthopaedic devices company. Speculation mounted last Friday morning (October 8) that the London-headquartered company was behind a 20% rise in Corin's share price. The Cirencester-based company has recently been making strong strides with its portfolio of "baby boomer" reconstructive devices - including the Cormet metal on metal hip resurfacing and mobile bearing Rotaglide knee joints - and made a 9% sales gain in the first half of 2004.